Editorial by Dan Roberts, Editor-in-Chief Prevent Blindness Since 1908, Prevent Blindness has been living up to its name by educating the public about early prevention and detection. It has done this by way of vision screenings, educational programs, research support, and advocacy. But the organization hasn’t stopped there. It realizes that preventing blindness means more […]
Courtesy: National Eye Institute, National Institutes of Health (NEI/NIH) A new study offers an explanation for how years of chronic sunlight exposure can increase the risk of cataract, a clouding of the eye lens that typically occurs with aging. The study firms up a link between the sun’s damaging rays and a process called oxidative […]
(Updated 4/17/16) On June 24, 2014, Ohr Pharmaceutical, Inc. announced positive top-line interim results for its Phase 2 clinical trial of Squalamine eye drops in patients with wet age-related macular degeneration (wet AMD). The data demonstrated a positive benefit in multiple visual function including a gain in visual acuity of +10.4 letters with Squalamine eye […]
Phase II Clinical Trial to Begin This Year StemCells, Inc. yesterday announced that, based on positive interim results, it has closed enrollment in its Phase I/II clinical trial for dry age-related macular degeneration (AMD) in order to focus its efforts on a follow-on Phase II randomized, controlled proof-of-concept study. Exceeding the company’s expectations, interim results showed […]
Researchers from Massachusetts Eye and Ear/Schepens Eye Research Institute, Harvard Medical School and other institutions have demonstrated for the first time that the omega-3 long-chain polyunsaturated fatty acids (LCPUFAs), DHA and EPA, can inhibit choroidal neovascularization (CNV). Their findings will be published in PNAS Online Early Edition the week of June 16-20, 2014. “These are […]